Drug
Antihemophilic Factor
Antihemophilic Factor: highest development phase Phase 2/3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Antihemophilic factor, recombinant, manufactured protein-free NCT00157053 | Phase 2/3 | Hemophilia A |
Latest
No recent events.
Follow Antihemophilic Factor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.